[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588403":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":27,"locations":33,"responsibleParty":51,"collaborators":56,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":97,"sex":103,"minAge":24,"maxAge":24,"enrollmentInfo":104,"targetDuration":24,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":24,"overallStatus":36,"whyStopped":24,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Norwegian Department of Health and Social Affairs","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"eFTR","EXPERIMENTAL","endoscopic full thickness resection",[13],"Procedure: eFTR",{"label":15,"type":16,"description":17,"interventionNames":18},"Surgery","ACTIVE_COMPARATOR","standard-of-care surgery",[19],"Procedure: Surgery",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"PROCEDURE",[9],null,{"type":22,"name":15,"description":17,"armGroupLabels":26,"otherNames":24},[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},"MICHAEL BRETTHAUER, MD PhD","CONTACT","+4790132480","michael.bretthauer@medisin.uio.no",[34],{"facility":35,"status":36,"city":37,"state":24,"zip":24,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Medical University of Gdańsk","RECRUITING","Gdansk","Poland","PL",{"type":41,"coordinates":42},"Point",[43,44],18.64912,54.35227,{"lat":44,"lon":43},[47],{"name":48,"role":30,"phone":49,"phoneExt":24,"email":50},"Piotr Spychalski, MD PhD","90132480","piotr.spychalski@gmail.com",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":55,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Michael Bretthauer","Professor","Oslo University Hospital",[57,60,62,64,67,69,71,73,75,77,79,81,83,85,87,89,91,93],{"name":58,"class":59},"Medical University of Gdansk","OTHER",{"name":61,"class":59},"Vestre Viken Hospital Trust",{"name":63,"class":59},"Universitätsklinikum Hamburg-Eppendorf",{"name":65,"class":66},"Institute of Oncology in Warsaw","UNKNOWN",{"name":68,"class":59},"Karolinska Institutet",{"name":70,"class":59},"University Hospital, Limoges",{"name":72,"class":59},"University Hospital, Akershus",{"name":74,"class":59},"University of Roma La Sapienza",{"name":76,"class":59},"Hospital Clinic of Barcelona",{"name":78,"class":66},"Leuven University Medical Center",{"name":80,"class":59},"University Hospital, Ghent",{"name":82,"class":6},"Sorlandet Hospital HF",{"name":84,"class":66},"Northern Norway Regional Health Trust",{"name":86,"class":6},"Helse Stavanger HF",{"name":88,"class":59},"Haukeland University Hospital",{"name":90,"class":59},"St. Olavs Hospital",{"name":92,"class":59},"University of Oslo",{"name":94,"class":66},"Frontier Science Foundation","100588403","phase-3-endoscopic-therapy-or-surgery-for-early-colon-cancer-100588403",false,"NCT06940947","Endoscopic Therapy Or Surgery for Early Colon Cancer","Endoscopic THerapy Or Surgery for Early Colon Cancer (ETHOS)","ETHOS","Inclusion Criteria:\n\n* Newly diagnosed biopsy-confirmed colon cancer (adenocarcinoma) with macroscopic suspicion of submucosal invasion considered removable by EFTR as deemed by the local multidisciplinary team (MDT) at the participating center\n* Size ≤20 mm in diameter as deemed by the colonoscopist\n* No presence of histopathological high-risk features in biopsy (high grade tumor growth, budding grade 2 or 3, or lymphovascular invasion)\n* Patient eligible for surgical removal as deemed by the local MDT at the participating center\n* Endoscopic images or video of the tumor\n* No sign of disease beyond T2N0M0 on pre-treatment imaging, biopsy sampling, and radiographic and clinical evaluation\n* No contraindication for any of the two treatment arms\n* Written informed consent\n* No prior or synchronous CRC\n* No other malignancy which is not cured\n* No more than 10 adenomas or serrated polyps\n* No genetic cancer syndrome (adenomatous or serrated polyposis syndrome; Lynch or Lynch-like syndrome)\n* No inflammatory bowel disease","ALL",{"count":105,"type":106},434,"ESTIMATED","INTERVENTIONAL",[109],"PHASE3","The trial is a randomized head-to-head comparison of the benefits, harms and burdens of endoscopic full-thickness resection (eFTR), a novel, minimally invasive endoscopic treatment modality, for early colon cancer as compared to standard-of-care surgery.",[112],"Colon Cancer","2025-11-17",{"date":115,"type":116},"2025-11-20","ACTUAL",{"date":118,"type":116},"2025-08-25",{"date":120,"type":106},"2033-09-01",{"name":5,"class":6},1]